NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses

Vaccine strategies that target dendritic cells to elicit potent cellular immunity are the subject of intense research. Here we report that the genetically engineered yeast Saccharomyces cerevisiae, expressing the full‐length tumour‐associated antigen NY‐ESO‐1, is a versatile host for protein production. Exposing dendritic cells (DCs) to soluble NY‐ESO‐1 protein linked to the yeast a‐agglutinin 2 protein (Aga2p) protein resulted in protein uptake, processing and MHC class I cross‐presentation of NY‐ESO‐1‐derived peptides. The process of antigen uptake and cross‐presentation was dependent on the glycosylation pattern of NY‐ESO‐1‐Aga2p protein and the presence of accessible mannose receptors. In addition, NY‐ESO‐1‐Aga2p protein uptake by dendritic cells resulted in recognition by HLA‐DP4 NY‐ESO‐1‐specific CD4+ T cells, indicating MHC class II presentation. Finally, vaccination of mice with yeast‐derived NY‐ESO‐1‐Aga2p protein led to an enhanced humoral and cellular immune response, when compared to the bacterially expressed NY‐ESO‐1 protein. Together, these data demonstrate that yeast‐derived full‐length NY‐ESO‐1‐Aga2p protein is processed and presented efficiently by MHC class I and II complexes and warrants clinical trials to determine the potential value of S. cerevisiae as a host for cancer vaccine development. Copyright © 2010 John Wiley & Sons, Ltd.

[1]  S. Vlahopoulos,et al.  Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin. , 2009, Vaccine.

[2]  K. Wittrup,et al.  Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles , 2008, Journal of immunotherapy.

[3]  J. Irache,et al.  Mannose-targeted systems for the delivery of therapeutics , 2008, Expert opinion on drug delivery.

[4]  J. Irache,et al.  Mannose-targeted systems for the delivery of therapeutics. , 2008, Expert opinion on drug delivery.

[5]  J. Beran.  Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. , 2008, Expert opinion on biological therapy.

[6]  S. Levitz,et al.  Effect of Differential N-linked and O-linked Mannosylation on Recognition of Fungal Antigens by Dendritic Cells , 2007, PloS one.

[7]  Jenny R. Roberts,et al.  A Comparison of the Pulmonary Inflammatory Potential of Different Components of Yeast Cell Wall , 2007, Journal of toxicology and environmental health. Part A.

[8]  B. Henrissat,et al.  Membrane association is a determinant for substrate recognition by PMT4 protein O-mannosyltransferases , 2007, Proceedings of the National Academy of Sciences.

[9]  G. Lauer,et al.  Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. , 2007, Vaccine.

[10]  A. Meyerhans,et al.  Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. , 2006, Vaccine.

[11]  Bent K Jakobsen,et al.  Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors , 2006, The Journal of Immunology.

[12]  D. Jäger,et al.  Identification of new NY‐ESO‐1 epitopes recognized by CD4+ T cells and presented by HLA‐DQ B1 03011 , 2006, International journal of cancer.

[13]  M. Pfreundschuh,et al.  Serological identification of breast cancer‐related antigens from a Saccharomyces cerevisiae surface display library , 2005, International journal of cancer.

[14]  Zheng-hong Yuan,et al.  Vaccination with recombinant HBsAg-HBIG complex in healthy adults. , 2005, Vaccine.

[15]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[16]  M. Schaller,et al.  Toll-like receptors as key mediators in innate antifungal immunity. , 2004, Medical mycology.

[17]  Yao-Tseng Chen,et al.  IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Pfreundschuh,et al.  Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments , 2004, European journal of immunology.

[19]  Julio Aliberti,et al.  Turning it on and off: regulation of dendritic cell function in Toxoplasma gondii infection , 2004, Immunological reviews.

[20]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Luft,et al.  NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors , 2004, Clinical Cancer Research.

[22]  G. Fink,et al.  A Saccharomyces cerevisiae mutant with increased virulence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Keating,et al.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. , 2003, Drugs.

[24]  S. Aamdal,et al.  Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.

[25]  Danila Valmori,et al.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.

[26]  V. Kurup,et al.  Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. , 2002, Microbes and infection.

[27]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Andreas Suhrbier,et al.  Polytope vaccines for the codelivery of multiple CD8T-cell epitopes , 2002, Expert review of vaccines.

[29]  P. Rod Dunbar,et al.  Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1 , 2002, The Journal of Immunology.

[30]  Laurence Zitvogel,et al.  Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.

[31]  Adrian Ozinsky,et al.  Phagocytosis of microbes: complexity in action. , 2002, Annual review of immunology.

[32]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[33]  J. Sohn,et al.  Purification of Soluble β-Glucan with Immune-enhancing Activity from the Cell Wall of Yeast , 2001, Bioscience, biotechnology, and biochemistry.

[34]  R. Levy,et al.  Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine1 , 2000, The Journal of Immunology.

[35]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[36]  D. Jäger,et al.  Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.

[37]  R. Steinman,et al.  Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells , 1998, The Journal of experimental medicine.

[38]  J. Drijfhout,et al.  Mannose receptor‐mediated uptake of antigens strongly enhances HLA class II‐restricted antigen presentation by cultured dendritic cells , 1997, European journal of immunology.

[39]  M. Bevan,et al.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. , 1997, Blood.

[40]  A. Lanzavecchia,et al.  Mannose receptor mediated antigen uptake and presentation in human dendritic cells. , 1997, Advances in experimental medicine and biology.

[41]  J. Drijfhout,et al.  Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendritic cells. , 1997, Advances in experimental medicine and biology.

[42]  F. Klis,et al.  Immobilizing proteins on the surface of yeast cells. , 1996, Trends in biotechnology.

[43]  R. Schiestl,et al.  Improved method for high efficiency transformation of intact yeast cells. , 1992, Nucleic acids research.